Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) have earned a consensus rating of “Buy” from the fourteen brokerages that are currently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $151.83.

A number of research analysts have recently commented on the stock. Maxim Group downgraded shares of GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating and set a $61.00 price objective for the company. in a research note on Tuesday, August 8th. BidaskClub downgraded shares of GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Leerink Swann reaffirmed an “outperform” rating and set a $160.00 price objective (down previously from $162.00) on shares of GW Pharmaceuticals PLC in a research note on Thursday, August 10th. Cantor Fitzgerald set a $208.00 price objective on shares of GW Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Tuesday, August 8th. Finally, Evercore ISI assumed coverage on shares of GW Pharmaceuticals PLC in a research note on Wednesday, August 16th. They set an “outperform” rating and a $154.00 price objective for the company.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/25/gw-pharmaceuticals-plc-gwph-receives-151-83-average-target-price-from-analysts.html.

GW Pharmaceuticals PLC (NASDAQ GWPH) traded down 1.00% during mid-day trading on Tuesday, hitting $101.92. 52,719 shares of the stock were exchanged. The stock’s market cap is $2.58 billion. GW Pharmaceuticals PLC has a 52-week low of $79.71 and a 52-week high of $137.88. The stock’s 50 day moving average is $107.43 and its 200 day moving average is $112.42.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($2.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.73) by $0.34. GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. The company had revenue of $3.14 million for the quarter, compared to analyst estimates of $2.10 million. During the same period in the prior year, the company earned ($0.05) EPS. Analysts forecast that GW Pharmaceuticals PLC will post ($6.10) EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of GWPH. Karp Capital Management Corp acquired a new stake in GW Pharmaceuticals PLC during the first quarter worth about $365,000. Pictet Asset Management Ltd. increased its stake in GW Pharmaceuticals PLC by 81.1% in the first quarter. Pictet Asset Management Ltd. now owns 128,571 shares of the biopharmaceutical company’s stock worth $15,549,000 after buying an additional 57,578 shares during the period. Nwam LLC acquired a new stake in GW Pharmaceuticals PLC during the first quarter worth about $208,000. Eqis Capital Management Inc. acquired a new stake in GW Pharmaceuticals PLC during the first quarter worth about $284,000. Finally, ING Groep NV increased its stake in GW Pharmaceuticals PLC by 89.5% in the first quarter. ING Groep NV now owns 19,222 shares of the biopharmaceutical company’s stock worth $2,325,000 after buying an additional 9,078 shares during the period. 74.98% of the stock is owned by hedge funds and other institutional investors.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.